Watchlist Price Alert

Apellis Pharmaceuticals I... (APLS)

NASDAQ: APLS · Real-Time Price · USD

18.27

0.28 (1.56%)

At close: May 08, 2025, 1:14 PM

1.56% (1D)

Bid	18.19
Market Cap	2.3B
Revenue (ttm)	781.37M
Net Income (ttm)	-197.88M
EPS (ttm)	-1.6
PE Ratio (ttm)	-11.42
Forward PE	112.41
Analyst	Buy

Ask	18.35
Volume	1,090,101
Avg. Volume (20D)	2,290,008
Open	17.78
Previous Close	17.99
Day's Range	17.37 - 18.31
52-Week Range	16.65 - 43.99
Beta	0.72

About APLS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol APLS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for APLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

Apellis Pharmaceuticals has released their quartely earnings on May 7, 2025:

Revenue of $166.8M misses estimates by $30.8M, with -3.21% YoY decline.

EPS of -0.74 misses estimates by -0.40, with -37.04% YoY decline.

Why Price Moved

1 day ago New

-5.91%

Apellis Pharmaceuticals shares are trading lower a... Unlock content with Pro Subscription

1 month ago

+3.7%

Apellis Pharmaceuticals shares are trading higher after the company announced FDA acceptance, priority review of sNDA for EMPAVELI.

News

5 hours ago · zacks.com

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.

23 hours ago · fool.com

Why Apellis Pharmaceuticals Wilted on Wednesday

A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and the...

1 day ago · seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and ...

18 hours ago · zacks.com

Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall...

20 hours ago · zacks.com

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.

1 week ago · zacks.com

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

1 month ago · benzinga.com

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (p...

2 months ago · seekingalpha.com

Apellis Pharmaceuticals: A Mixed Bag

Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complica...

2 months ago · benzinga.com

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Last week, Apellis Pharmaceuticals Inc APLS reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the ...

Load More News